Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma With Shaheer Khan, DO
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma In honor of Melanoma Awareness Month, Oncology Data Advisor spoke with Dr. Shaheer Khan, an Assistant Professor of Medicine at Columbia University Irving Medical Center. Dr. Khan shares the promising results of two recent ...
Oncology Nursing Month With Maria Badillo and Sherry Adkins: Nursing Considerations for CAR T-Cell Therapy
Keira Smith
Expert Analysis
In honor of Oncology Nursing Month in May, Oncology Data Advisor is celebrating the stories of these essential members of the cancer care team. For this interview, editorial board member Maria Badillo, MSN, RN, OCN®, CCRP, speaks with Sherry Adkins, MSN, ANP-C, Advanced Practice Provider Supervisor at MD Anderson Cancer Center, about her groundbreaking research in the development of chimeric antigen (CAR) T-cell therapies and the critical role that oncology nurses play in caring for patients receiving this novel therapeutic strategy.  
Taking a Nuanced Approach to Testicular Cancer Management With Sam Kaffenberger, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Taking a Nuanced Approach to Testicular Cancer Management With Sam Kaffenberger, MD For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the m...
Can Digital Health Tools Improve Quality of Life in Multiple Myeloma? Insights from Neha Korde, MD, and Rahul Banerjee, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Can Digital Health Tools Improve Quality of Life in Multiple Myeloma? In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Ko...
Exploring Recent Advances in Testicular Cancer Surgery and Access to Care With Andrew Winer, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Exploring Recent Advances in Testicular Cancer Surgery and Access to Care This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery...
Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be cons...
Considering Venous Thromboembolism Risk Factors and Prophylaxis in Multiple Myeloma With Rajshekhar Chakraborty, MD, and Rahul Banerjee, MD
Keira Smith
Special Episode
Oncology Data Advisor™ · Considering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial B...
Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Food for Thought From Urvi Shah, MD, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah...
The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this r...
Advocating for Patients During Multiple Myeloma Clinical Trial Design and Post-Protocol: Manni Mohyuddin, MBBS, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Advocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial boar...
The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Dr. Augusto Villanueva, an Associate Professor of Medicine at Mount Sinai Hospital, discussed the role of the four main etiologies of hepatocellular carcinoma (HCC) in the response that patients may experience to treatment with immune checkpoint inhibitors. In this interview, Dr. Villanueva delves further into the question of whether etiology should play a part in immune-based treatment selection, as well as the role of liquid biopsy for patients newly diagnosed with HCC.  
Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS.  
World Cancer Day: An Expert Panel Discussion With Thomas Abrams, MD; Ulka Vaishampayan, MD; and Beth Sandy, MSN, CRNP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Cancer Day With Thomas Abrams, MD; Ulka Vaishampayan, MD; and Beth Sandy, MSN, CRNP In honor of World Cancer Day, members of the Oncology Data Advisor (ODA) editorial board gathered to discuss the latest advances and future directions in oncology research. Dr. Thomas Abrams, an Assistant Professor of Medicine at Harvard Medical School shared recent progress in the field of gastrointestinal cancers; Dr. Ulka Vaishampayan, a Professor of Internal Medicine at the University of Michigan Rogel Cancer Center provided insights into current trends in genitourinary cancer research; and Beth Sandy, MSN, CRNP, an outpatient thoracic oncology nurse practitioner at the University of Pennsylvania Abramson Cancer Center, discussed recent and future treatment advances in the field of lung cancer.  
Can Digital Life Coaching During Transplant for Multiple Myeloma Improve Quality of Life? Insights From Rahul Banerjee, MD, and Kelly Brassil, PhD, RN, FAAN
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Can Digital Life Coaching Improve Quality of Life in Transplant? Rahul Banerjee and Kelly Brassil Patients undergoing autologous stem cell transplant (ASCT) for multiple myeloma face significant challenges in quality of life, including anxiety, acute symptom burden, and decreased physical function. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Rahul Banerjee and Dr. Kelly Brassil presented their research regarding digital life coaching for this patient population. In this interview with Oncology Data Advisor, Dr. Banerjee and Dr. Brassil discuss their results from a prior pilot study on this topic, the design of an ongoing phase 2 trial to continue the research, and its implications for improving the quality of life for patients undergoing ASCT for multiple myeloma.  
Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  
Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In the Presidential Symposium at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Matthew Davids of Harvard Medical School discussed the current therapeutic strategies used to inhibit or reactivate mutant p53 in the treatment of hematologic malignancies. In this interview with Oncology Data Advisor, Dr. Davids delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.  
The Call to Understand Racial and Socioeconomic Disparities in Pediatric Acute Lymphoblastic Leukemia: Sumit Gupta, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Call to Understand Racial Disparities in Pediatric Acute Lymphoblastic Leukemia: Sumit Gupta, MD Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, a team of researchers led by Dr. Sumit Gupta of the University of Toronto investigated the impact of race, ethnicity, and socioeconomic status among young patients with ALL enrolled in Children's Oncology Group studies between 2004 and 2019. The investigators identified significant disparities in survival outcomes in association with these factors. In this interview, Dr. Gupta explains the importance of recognizing health disparities among pediatric patients with ALL and the changes that can be implemented to address them.  
Applying Recent Advances to Personalized Breast Cancer Care, A Breast Surgical Oncologist’s View: Brigid Killelea, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Applying Recent Advances to Personalized Breast Cancer Care: Brigid Killelea, MD, FACS Over recent years, numerous developments have occurred in the fields of breast cancer prevention, genetic testing, screening, and surgical procedures. In this interview, Dr. Brigid Killelea, Medical Director of Breast Surgery at Hartford HealthCare, explains strategies for incorporating these advances into the care of patients with breast cancer.
Making Strides in Breast Cancer Treatment With Richard Zelkowitz, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Making Strides in Breast Cancer Treatment With Richard Zelkowitz, MD Significant progress has been made in numerous facets of breast cancer care in recent years, including developments in treatment, imaging, pathology, radiation, and surgery. In this interview, Dr. Richard Zelkowitz, a Regional Medical Director of the Breast Program at Hartford HealthCare, highlights the advances that have been made and explains the importance of subspecialties in ensuring that patients with breast cancer receive the most individualized care possible.  
Breast Cancer Awareness Month: A Panel Discussion With Christine Samuel, Mikel Ross, and Lillie Shockney
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Breast Cancer Awareness Month With Christine Samuel, Mikel Ross, and Lillie Shockney In this recording of Oncology Data Advisor's Live Breast Cancer Panel, three noted experts in breast cancer management partake in a conversation about recent advances in treatment, strategies and integrative medicine modalities to minimize toxicity, and techniques for enabling patients with breast cancer to thrive throughout their diagnosis and treatment.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.